Posted by Michael Wonder on 27 Jan 2026
Novo's Ozempic to gain insurance coverage for diabetes in Korea from February under new criteria
23 January 2026 - Starting in February, Korea's national health insurance will cover Novo Nordisk's Ozempic pre-filled pen, which contains the active ingredient semaglutide, as a diabetes treatment.
The Ministry of Health and Welfare announced an administrative notice regarding the “Revised Details on the Application Criteria and Methods for Medical Benefits,” which is open for public comment until Monday. Accordingly, the semaglutide injection for type 2 diabetes, including the Ozempic pre-filled pen 2 mg, will be covered by medical benefits when administered to patients with type 2 diabetes.
